Evelo Biosciences announced that its first extracellular vesicle product candidate, EDP2939, has progressed to dosing in a Phase 2 psoriasis clinical trial after completing a safety and tolerability review from a first cohort of human volunteers. Safety and tolerability assessment of multiple ascending dose cohorts continues. Mark Bodmer, Ph.D., President of R&D and CSO of Evelo added, "EVs and EDP2939 show great promise as a new type of SINTAX medicine with potential for biologic-like efficacy based on three factors: the high intrinsic potency of EVs in preclinical models; the number and concentration of EVs that can be delivered in a single capsule; and the delivery to the target site of the proximal small intestine. We look forward to reporting EDP2939 psoriasis efficacy results, expected in the second half of this year."
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EVLO:
- Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
- Biotech Alert: Searches spiking for these stocks today
- Evelo Biosciences Collapses after Treatment Trial Fails
- Evelo double downgraded at Jefferies after atopic dermatitis cohorts fail
- Evelo Biosciences downgraded to Underperform from Buy at Jefferies